

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 December 2006 (21.12.2006)

PCT

(10) International Publication Number
WO 2006/133733 A1

(51) International Patent Classification:
A61K 9/51 (2006.01) A61K 9/62 (2006.01)

(21) International Application Number:
PCT/EP2005/012721

(22) International Filing Date: 13 June 2005 (13.06.2005)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (for all designated States except US): **FLAMEL TECHNOLOGIES** [FR/FR]; 33 Avenue du Docteur Georges Lévy, F-69200 Venissieux (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SOULA, Gérard** [FR/FR]; 33, rue Nungesser, F-69330 Meyzieu (FR). **GUIMBERTEAU, Florence** [FR/FR]; 3, route de la Garenne, F-33450 Montusson (FR). **DARGELAS, Frédéric** [FR/FR]; 16 rue de l'Université, F-69007 Lyon (FR). **SOULA, Rémi** [FR/FR]; 22, rue Bouteille, F-69007 Lyon (FR).

(74) Agents: **CABINET PLASSERAUD et al.**; 52, rue de la Victoire, F-75440 Paris Cedex 09 (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ORAL DOSAGE FORM COMPRISING AN ANTIMISUSE SYSTEM

(57) Abstract: An oral solid dosage form containing one or several active principle(s) having analgesic properties, the composition of said dosage form being such that it prevents the misuse of said dosage form through the liquid extraction of the active principle(s) contained therein, using commonly available solvents. Said oral solid dosage form containing at least one salt of at least one analgesic active principle, and an anti-misuse system comprising at least one quenching agent, said quenching agent being suitable for inducing complexation of said analgesic active principle salt when the analgesic active principle salt is improperly extracted, notably by a drug abuser, in vitro in solution from said oral solid dosage form.



WO 2006/133733 A1

ORAL DOSAGE FORM COMPRISING AN ANTIMISUSE SYSTEM

FIELD OF THE INVENTION

5

The present invention relates to an oral solid dosage forms containing one or several active principle(s) having analgesic properties, the composition of said dosage form being such that it prevents the intentional or unintentional misuse of said dosage form through the liquid extraction of the active principle(s) contained therein, using commonly available solvents.

10

More specifically, the analgesic active principle (AAP) is present in the oral solid dosage form is a pharmaceutically acceptable salt. In the present disclosure, the mention analgesic active principle means a pharmaceutically acceptable salt of analgesic active principle.

15

BACKGROUND OF THE INVENTION

Analgesics, and more particularly opioid or morphine derivatives, are often misused. Such misuse can be intentional or unintentional consumption of a solid oral drug containing an analgesic active principle, for a purpose other than that which is officially approved by the competent health authorities. This is a very complex and difficult problem to solve. The reason is that drug abuses and unfortunately now even teenagers have found way to recover the drug from tablets quite easily.

20

For example, today, teenagers prepare for parties on Saturday, a cocktail of vodka with Oxycodon that they extract easily from tablets, with water or alcohol. The process consists in crushing the tablet and pouring the powder into a glass of vodka or water and then, to wait long enough to extract almost completely all the morphines derivative. They use to do the preparation of the drug before they take it. This practice is widespread in US but also in Europe. This is becoming a real social concern addressed by social agencies but also by the Food and Drug Administration in US and European Agencies, who wish that dosage forms preventing misuse be developed.

25

There are other ways to misuse the type of opioid such as extracting the drug as described above and make an intra-venous injection or dry the drug in order to obtain a powder which can be inhaled.

30

There is a prior art describing different solution to avoid the misusage of opioids contained into a delivery systems.

Patent application US-A-2003/0224051 describes osmotic delivery dosage forms for the modified release of oxycodone. The dosage form comprises an oxycodone core or acceptable salts thereof, a semi-permeable membrane at least partially surrounding the core, an exit orifice through the membrane allowing the release of oxycodone. This type of
5 tablet allows an easy extraction by water for example after 12 hours or more and consequently does not provide a satisfactory solution against misuse.

Another way to avoid misuse of an opioid is to combine the opioid with its antagonist such as naltrexone. The WO-A-03/013479 patent describes an oral dosage form
10 comprising a therapeutically effective amount of an opioid analgesic; an opioid antagonist (naltrexone); and a bittering agent. When the drug abuser crushes the tablet, the opioid and its antagonist are released and the opioid effect is neutralised.

This system does not prevent extraction by water because, without crushing, the opioid can be extracted, contrary to naltrexone.
15

Published European patent application EP-A-1293209 describes a solid oral pharmaceutical dosage form with reduced potential for drug abuse. The oral dosage form of the invention is a sustained release dosage form based on an ion exchange resin which contains an opioid derivative. However, this dosage form does not prevent solvent
20 extraction with an extraction time longer than the normal release time of the drug. If said oral dosage form is left in a glass of water during 24 hours, most of the drug will be extracted.

As can be seen from the foregoing presentation of the prior art, different solutions are provided to prevent misuse of pharmaceutical opioids in modified release solid dosage
25 forms.

However, none of the solutions can prevent the extraction by water, alcohol or any other type of drinkable solvent.

30 OBJECTIVES OF THE INVENTION

In these circumstances, one of the main objectives of the instant invention is to fill in the prior art. Thus, an essential objective of the invention is to provide a new solid oral analgesic medicine, allowing for the prevention of oral misuse after a "long" liquid
35 extraction of the analgesic active principle, preferably without resorting to antagonists of the analgesic active principle. By "long liquid extraction", it is meant that the liquid extraction is planned by the drug abuser to last more than 10 minutes.

An essential objective of the invention is to provide a solid oral dosage form containing an analgesic active principle, said dosage form having the following features:

- Under normal prescribed condition of administration, the dosage form should have the desired therapeutic effect, for example during 12 hours or 24 hours;
- 5 • Under any attempt of improper extraction of the analgesic by a misuser, the oral dosage form will not be able to provide fast absorption of the analgesic into the blood circulation.

Another objective of the invention is to provide a new solid oral dosage form that prevents misuse by a long liquid extraction as well as a brief liquid extraction and/or by crushing.

10 Another objective of the invention is to provide a new solid oral analgesic dosage form:

- which can be administered easily to patients having difficulties to swallow large tablets, among which infants, children and the elderly;
- which permits the association of several analgesic active principles, or even other non-analgesic active principles, in a single dosage form, even when said active principles are not compatible between themselves and/or when said active principles have distinct release kinetics;
- 15 • which permits the provision of an oral pharmaceutical dosage form of analgesic active principle, or even other non-analgesic active principles, which is administered once a day or several times a day, it being possible to adjust easily and independently the release rate and the release time of said active principles.

A further objective of the invention is to provide an oral pharmaceutical dosage form of analgesic active principle, the *in vitro* dissolution profile of which is independent from the dose of analgesic active principle.

25 Another objective of the invention is to provide an oral pharmaceutical dosage form of analgesic active principle, which can be administered once a day and which limits the risks of tissue damage due to local over-concentration of said active principle.

Still a further objective of the invention is to provide an oral pharmaceutical dosage form of analgesic active principle which can be formulated into different galenical forms, such as tablets, powders, sachets, capsules and the like.

30 An essential objective of the invention is to provide a new solid oral drug that prevents misuse while not compromising the treatment of a patient who conforms to a regular therapy, in particular as regards this patient's needs in terms of dose of active principle.

35 Yet another objective of the invention is to provide a new solid oral drug that prevents misuse, which is easily prepared and the preparation process of which does not unduly increase its manufacturing cost.

SUMMARY OF THE INVENTION

To achieve these objectives, it is to the inventor's credit to have discovered means suitable to quench an analgesic active principle such as an opioid when it is extracted from the dosage form for misuse purpose.

The dosage form according to the invention has the following essential features:

- Under normal prescribed condition of administration, the dosage form has the desired therapeutic effect for example during 12 hours or 24 hours;
- Under any attempt to extract the analgesic, with or without crushing, the analgesic is quenched *in vitro* by a safe and even generally recognized as safe substance (GRASS) in order to avoid its fast absorption into the blood circulation and hence neutralize the fast action of the drug;
- The quenching agent forms a complex which is poorly soluble in water at any physiological pH from the stomach to the colon.

The invention provides a solid oral dosage form that contains at least one quenching agent, this quenching agent being suitable for inducing complexation of the analgesic active principle when the analgesic salt is released in solution from the solid oral dosage form.

The invention further provides a solid oral dosage form for which the quenching agent cannot be removed from the system.

In other words, the invention relates to an oral solid dosage form containing at least one salt of at least one analgesic active principle, and an anti-misuse system comprising at least one quenching agent, said quenching agent being suitable for inducing complexation of said analgesic active principle salt when the analgesic active principle salt is improperly extracted, notably by a drug abuser, *in vitro* in solution from said oral solid dosage form.

This solution was not self evident as it was necessary to define an efficient but a safe and generally recognized as safe substance quenching additive in the case where the drug abuser intends to extract the drug. At the same time, the system should permit to release the drug in the body following the targeted pharmacokinetic profile. This new system will be called hereafter "Trigger Lock" system.

The invention provides a solid dosage form comprising an encapsulated analgesic active principle in a salt form and at least one encapsulated quenching agent. Said quenching agent is released as such speed that it can complex analgesic active agent principle when it is itself release by extraction from the oral solid dosage form. The quenching takes place when the quenching agent and the analgesic (e.g. for example the opioid) have been extracted *in vitro* by the solvent, forming a complex poorly soluble in the stomach medium.

This last characteristic of the Trigger Lock system ensures that ingestion of the complex does not lead to any fast regeneration and/or fast extraction of the analgesic active principle once absorbed by the drug abuser. Thus, the massive absorption of the analgesic, as desired by the drug abuser, and the consequent massive blood concentration of analgesic, is avoided.

According to another remarkable feature of the invention, the analgesic active principle and the quenching agent are both in a modified release form. For example both the analgesic and the quenching agent could be released according to a sustained release kinetics. Thus, it is impossible, or at least very difficult, to extract separately *in vitro* the analgesic active principle and the quencher. In other words, the analgesic active principle and quenching agent are necessarily extracted together and thus form a poorly soluble complex.

When the dosage form according to the instant invention is administered orally in accordance with the prescriptions of the health authorities, said dosage form releases slowly both the analgesic active principle and the quenching agent in the gastric fluids where they are both diluted, so that no complexation occurs. Then, the analgesic active principle can be correctly bio-absorbed.

Dosage forms containing a plurality of microparticles are preferred. It is also the inventors' credit to have designed a microparticulate system comprising a first microparticles population with the drug and a second microparticles population with the quenching agent. Both microparticles populations comprise more than 1,000 microparticles. This permits to obtain a fast dispersion of all the microparticles, thereby avoiding interaction of the quenching agent and the analgesic active principle in the body.

It is also one element of the invention to propose a delayed release for the quencher in order to have enough time in the body to disperse the microparticles before the quencher neutralizes the analgesic active principle.

After administration of the dosage form according the prescriptions of the health authorities, the analgesic is slowly released but the release of the quencher starts only after a lag time of typically 0.25 to 3 hours. During this lag time, the microparticles of analgesic and the microparticles containing the quencher are broadly dispersed in the gastro-intestinal tract and the quencher can no longer neutralize the analgesic.

Such a modified release of the quencher in the stomach, optionally after a modified lag time is conveniently obtained by coating the microparticles containing the quenching agent with a film coating, the composition of which is detailed hereinbelow.

A further advantage of microparticulate dosage forms is that they are less easy to
5 crush or to chew.

Preferably, the complex is poorly soluble in common solvents such as a water-ethanol mixture. In other words, the concentration of analgesic active principle remaining in solution is low, i.e. the amount of analgesic active principle in solution is not sufficient
10 to produce the effect desired by the drug abuser.

Preferably, the novel oral solid dosage form of the instant invention does not contain antagonists of the analgesic active principle.

15

DETAILED DESCRIPTION OF THE INVENTION

The concept at the root of the invention is to include within a solid oral dosage form a quenching agent (quencher), namely a salt. This salt comprises an ion which has a
20 polarity opposite to that of the analgesic active principle in solution. Preferably it is an organic ion. It can also be a metallic ion.

When in solution, the said ion replaces the initial counter-ion of the analgesic active principle, leading to a substantively insoluble complex. As a consequence, the analgesic active principle is no longer free in solution. By "no longer free in solution" or "low
25 concentration" is meant that the concentration of analgesic active principle remaining in solution is below the concentration desired by the drug abuser, or it is not sufficient to produce the desired effect by the drug abuser.

On the contrary, when the oral dosage form is administered according to the regimen prescribed by the health authorities, the dilution of the quenching agents in the
30 gastrointestinal tract fluids is sufficient to prevent the reaction of the quenching agent with the analgesic active principle. Thus the therapeutic effect of the analgesic active principle is met.

Preferably, the active principles considered in the instant disclosure are analgesic active principles. Non-analgesic active principles can also be included. In this
35 specification, the mention of "an active principle" or "the active principle" includes both the singular and the plural, and the mixture of different active principles.

The same convention applies to the mention of "a quenching agent" or "the quenching agent". Both include the singular, the plural and mixtures of different quenching agents.

By "oral dosage form" is meant in this disclosure any dosage form wherein the
5 active principle is comprised in tablets (monolithic dosage form) or in microparticles (multimicroparticulate dosage form). These dosage forms can be immediate release dosage forms or modified release dosage forms. In the latter case, the tablet or the microparticle core containing the active principle can be coated with a polymer coating that controls the release rate of the active principle after oral administration.

10 By "immediate release dosage form" is meant the release by a dosage form of the major part of the active principle dose in a short time, for instance, 70 % of the active principle are released in 1 hour, preferably in 30 min., at any pH between 1.4 and 6.8, during an *in vitro* dissolution test.

By "modified release dosage form" is meant any dosage form wherein at least a
15 fraction of the active principle is released at a lower rate than in an immediate release dosage form. This fraction can be comprised between 1 and 100 %, preferably, between 10 and 100 %, and even more preferably between 30 and 100 %. A modified release dosage form can comprise an immediate release phase and a sustained or delayed release phase. Modified release dosage forms are well known in the art, see for instance Remington: *The*
20 *science and practice of pharmacy*, 19ème edition, Mack publishing Co. Pennsylvania, USA. Modified release comprises, notably, sustained release, delayed release, and pulsed release.

By "long liquid extraction", it is meant that the liquid extraction is planned by the drug abuser to last more than 10 minutes.

25 By "household solvent" or "common solvent", it is meant a liquid that can usually be found in a household and that can be used as an extraction solvent. For instance, it designates water, alcohol, alcoholic beverages, sodas, vinegar, and/or hydrogen peroxide, and mixtures thereof. Water-ethanol mixtures are encompassed as well.

Other definitions are given in the instant disclosure.

30

The quenching agents used to trap the analgesic active principle are innocuous to the regular user. These quenching agents are pharmacologically inert, approved by the Pharmacopoeia and health authorities in charge of market approval of drugs.

Preferably, the quenching agent comprises a salt, said salt containing ions which
35 form a complex with said analgesic active principle in solution. Said ions are preferably organic ions that have a polarity opposite to that of the analgesic active principle salt in solution. When the analgesic active principle salt is in the form of an anion in solution, the quenching agent comprises an organic cation, a metallic cation or a mixture thereof.

Similarly, when the analgesic active principle salt is in the form of a cation in solution, the quenching agent comprises an organic anion.

For example, the following salts containing an organic anion can be listed:

- organic anionic salts, such as sodium dodecyl sulfate or sodium docusate;
- 5 • anionic polymers, such as (meth)acrylic copolymers (for instance Eudragit® S et L), crosslinked acrylic polyacids (for instance, Carbopol), cellulose carboxymethylcellulose and its derivatives, crosslinked carboxymethylcellulose and its derivatives and other polysaccharides (for instance, alginate, xanthane or arabic gum), alginate (sulfonate)propylene glycol;
- 10 • mono- or polyvalent salts, such as glucuronates, citrates, acetates, gluconates, succinates, phosphates, glycerophosphates, lactates, trisilicates, fumarates, adipates, benzoates, salicylates, tartrates, sulfonamides, acesulfames;
- saponified fatty acids, such as the salts of acetic acid, succinic acid, citric acid, stearic acid, palmitic acid, and self emulsifying glyceryl mono-oleates;
- 15 • polyamino acid, proteins or peptides, such as albumins, caseins, globulins and enzymes;
- and mixtures thereof.

20 The quenching agent can be an anionic exchange resin, in which case the analgesic active principle does not form a complex with the ion exchange resin. For instance, the quenching agent can be a salt of an anionic exchange resin, the cation of which is H^+ , a metallic cation and/or NH_4^+ . More precisely, said ion exchange resin is comprised in a first phase separate from a second phase, said second phase comprising said analgesic active principle.

25

In another embodiment, said ion having a polarity opposite to that of the analgesic active principle salt in solution, is a metallic cation, an organic cation, or a mixture thereof. For example, the following salts containing an organic cation or a metallic cation can be listed:

- 30 • metallic cationic salts for example of Ca, Fe, Mg, Zn, in the form of acesulfames, acetates, adipates, benzoates, carbonates, chlorides, citrates, fluorides, fumarates, gluconates, glucuronates, glycerophosphates, hydroxides, iodates, iodides, lactates, oxides, phosphates, trisilicates, phosphates, salicylates, succinates, sulfonamides, tartrates salts;
- 35 • organic cationic salts, such as quaternary ammonium salts, in particular trimethyl tetradecyl ammonium bromide or benzethonium chloride;
- cationic polymers, such as chitosan and (meth)acrylic copolymers (for instance, Eudragit® RS, RL ou E);

- polyamino acid, proteins or peptides;
- and mixtures thereof.

5 The quenching agent is selected in view of the chemical properties of the active principle it aims, in particular its ionic form in solution.

For the liquid extraction of the analgesic active principle, the dosage form containing the active principle is generally placed into an extraction solvent, such as a household liquid (water, organic solvents, sodas, alcoholic beverages) for a time period
10 longer than 10 minutes.

Preferably, the dosage form according to the invention does not contain an active principle that is an antagonist to the analgesic active principle, particularly in the case of an opioid agonist.

15 Preferably, the dosage form according to the invention comprises modified release units of said analgesic active principle and modified release units of said quenching agent. For instance, said modified release units comprise microparticles selected from the group comprising: sustained release microparticles, delayed release microparticles, pulsed release microparticles, and mixtures thereof.

20 A preferred embodiment is a multimicroparticulate dosage form. It is preferred that, when the dosage form comprises microparticles of analgesic active principle and microparticles of quenching agent, said microparticles have the same size distribution, the same density and are not sievable.

Said dosage form can also be a monolithic dosage form.

25 According to a preferred embodiment, the quencher contained in the oral solid dosage form of the invention is released following a modified release kinetic. Preferably, the quencher is contained in film coated microparticles, and most preferably, in microparticles coated with the same film coating as that used to coat the microparticles
30 containing the analgesic active principle.

According to a preferred embodiment, the dosage form comprises a further antismuse agent. Said further antismuse agent aims at preventing drug abuse by injection, after a possible crushing and liquid extraction. In an additional embodiment, said further
35 antismuse agents are provided to prevent drug abuse by inhalation, after a possible crushing and liquid extraction. Therefor, said further antismuse agent comprises an anti-crushing agent (a) and/or a viscosity agent (b).

Preferably, said anti-crushing agent (a) comprises:

- a protective over-coating on said microparticles, said over-coating having at least one of the following features:
 - viscoelastic properties, to absorb the energy dissipated during crushing;
 - 5 – a low cohesivity, to favor breaking of the over-coating rather than breaking of the microparticles during crushing;
 - a low surface energy, to favor gliding of the microparticles one on the other during crushing;
 - an ability to form a paste under high shear,
- 10 • and/or free additives, i.e. additives that are not contained in nor borne over microparticles, said additives being suitable to impair, or even to prevent completely, the crushing of the pharmaceutical dosage form containing said analgesic active principle.

In the case where an over-coating is provided to protect the dosage form, such as microparticles, the over-coating is prepared so that a non-immediate release of the
15 analgesic active principle takes place even after the dosage form has been crushed.

More precisely, the over-coating of the dosage form comprises:

- (i) at least one film forming polymer insuring the cohesion of the over-coating;
- and at least one of the following compounds:
 - (ii) a lubricant/lump agent
 - 20 – (iii) a viscoelastic compound
 - (iv) a plasticizer.

In practice, said film-forming polymer (i) is selected from the group comprising cellulose derivatives, acrylic polymers and mixtures thereof.

25

Said lubricant/lump agent (ii) is selected from the group comprising:

- stearic acid, stearates, preferably calcium stearate, zinc stearate or magnesium stearate,
- magnesium oxide,
- poloxamers,
- 30 • sodium benzoate,
- anionic, cationic or non-ionic surfactants,
- starch, preferably corn starch,
- talc,
- colloidal silica,
- 35 • waxes, preferably hydrogenated vegetable oils, and more preferably: cotton hydrogenated oils, soybean hydrogenated oils, palm hydrogenated oils, glycerol behenate, castor hydrogenated oils, tristearines, tripalmitines, trimyristines, yellow wax, white wax, hard fat, dairy anhydrous fat, lanolins, glycerol palmitostearate, glycerol stearates, lauric

acid macrogolglycerids, cetyl alcohols, polyglycryle di-isostearate, diethylene glycol monostearate, ethylene monostearate, omega-3 fatty acids, and mixtures thereof,

- suppository fatty base, comprising glycerine, triglycerids, theobroma oils, cocoa butter, and mixtures thereof,
- 5 • mixtures thereof.

Said viscoelastic compound (iii) is selected from the group comprising:

- poly-N-vinylamides,
- gums,
- 10 • fatty alcohols,
- poly-N-vinyl-lactams,
- polyvinyl alcohols,
- polyoxiethylenes,
- polyethylene glycols,
- 15 • polydextroses,
- hydrogenated mono-, di- and polysaccharides,
- polyvinylpyrrolidones, these being preferred,
- and mixtures thereof.

20 Said plasticizer (iv) is selected from the group comprising:

- glycerol, glycerol esters, preferably acetylated glycerides, glycerylmonostearates, glyceryltriacetate, glyceryltributyrate,
- phthalates, preferably: dibutylphthalate, diethylphthalate, dimethylphthalate, dioctylphthalate,
- 25 • citrates, preferably: acetyltributylcitrate, acetyltriethylcitrate, tributylcitrate, triethylcitrate,
- sebacates, preferably: diethylsebacate, dibutylsebacate,
- adipates,
- azelates,
- 30 • benzoates,
- vegetable oils, preferably: cotton oils, soybean oils, palm oils, castor oils, and mixtures thereof,
- fumarates, preferably: diethylfumarate,
- malates, preferably: diethylmalate,
- 35 • oxalates, preferably: diethyloxalate,
- succinates; preferably: dibutylsuccinate,
- butyrates,
- cetyl alcohol esters,

- triacetine,
- malonates, preferably: diethylmalonate,
- and mixtures thereof.

5 The additive possibly comprised in the anti-crushing agent (a) is preferably selected from the group comprising: compression agents, and/or inert microbeads, and/or gums, and/or viscoelastic compound as defined above.

10 The viscosity agents, intended to prevent misuse of the analgesic active principle after a possible liquid extraction, aim at increasing the viscosity of the extracted liquid, so as to impair misuse, notably by injection.

 The viscosity agents are preferably located in microcapsules containing said viscosity agents, and/or on microcapsules containing the active principle, and/or in a partial or total overcoating of said dosage form, and/or free from said dosage form.

15 Preferably, said viscosity agent is selected from the group comprising:

- acrylic polyacids and derivatives thereof, and/or
- polyoxyethylenes, and/or
- polyvinyl alcohol, and/or
- polyvinylpyrrolidones, and/or
- 20 • gelatins
- cellulose derivatives, for instance hydroxypropylmethylcellulose, methylcellulose, hydroxyethylcellulose, carboxymethylcellulose, hydroxypropylcellulose, and/or
- polysaccharides, preferably from the group comprising sodium alginate, pectins, guar, xanthanes, carraghenanes, gellanes, and/or
- 25 • mixtures thereof.

 The oral dosage form according to the invention presents at least one of the following remarkable features:

- It cannot, or with difficulty, be transformed into a dry inhalable form;
- 30 • It cannot, or with difficulty, be transformed into a liquid injectable form;
- The extraction of the analgesic active principle by chewing is not efficient;
- Moreover, the liquid extraction of the analgesic active principle leads to the complexation of said active principle, thereby rendering it useless by the oral route.

35 The dosage form according to the invention can comprise, in addition to micro-units made of modified release microcapsules of analgesic active principle, micro-units of analgesic active principle other than microcapsules, among which immediate release

micro-granules. Advantageously, said micro-granules are not coated and are of the same type as those used to prepare microcapsules according to the invention.

Advantageously, said analgesic active principle is an opioid active principle, preferably an opioid agonist. Preferably, said opioid active principle is selected from the group comprising: anileridine, acetorphine, acetylalphamethylfentanyl, acetyldihydrocodeine, acetylmethadol, alfentanil, allylprodine, alphacetylmethadol, alphameprodine, alphaprodine, alphamethadol, alphamethylfentanyl, alpha-methylthiofentanyl, alphaprodine, anileridine, atropine, butorphanol, benzethidine, benzylmorphine, beta-hydroxyfentanyl, beta-hydroxy-methyl-3-fentanyl, betacetylmethadol, betameprodine, betamethadol, betaprodine, bezitramide, buprenorphine, butyrate de dioxaphetyl, clonitazene, cyclazocine, cannabis, cetobemidone, clonitazene, codeine, coca, cocaïne, codoxime, dezocine, dimenoxadol, dioxaphetylbutyrate, dipipanone, desomorphine, dextromoramide, dextropropoxyphene, diampromide, diethyl-thiambutene, difenoxine, dihydrocodeine, dihydroetorphine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, diphenoxylate, dipipanone, drotebanol, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, ecgonine, ephedrine, ethylmethylthiambutene, ethylmorphine, etonitazene, etorphine, etoxeridine, fentanyl, furethidine, heroine, hydrocodone, hydromorphanol, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levallorphan, lofentanil, levomethorphan, levomoramide, levophenacymorphane, levorphanol, meptazinol, meperidine, metazocine, methadone, methyl-desorphine, methyl-dihydro-morphine, methylphenidate, methyl-3-thiofentanyl, methyl-3-fentanyl, metopon, moramide, morpheridine, morphine, mppp, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, nicocodine, nicodicodine, nicomorphine, noracymethadol, norcodeine, norlevorphanol, normethadone, normorphine, norpipanone, opium, oxycodone, oxymorphine, papaveretum, phenadoxone, phenoperidine, promedol, properidine, propiram, propoxyphene para-fluorofentanyl, pepap, pentazocine, pethidine, phenampromide, phenazocine, phenomorphane, phenoperidine, pholcodine, piminodine, piritramide, proheptazine, propanolol, properidine, propiram, racemethorphan, racemoramide, racemorphane, remifentanyl, sufentanyl, thebaine, thebaine, thiofentanyl, tilidine, trimeperidine, tramadol, pharmacologically acceptable salts thereof and their mixtures.

The oral dosage forms according to the instant invention can comprise at least one further active principle, distinct from an analgesic active principle. This non-analgesic active principle is preferably selected from the group comprising: anti-depressants, amphetamines, anorectics, pain killers, antiepileptics, anitmigraines, antiparkinson agents, antitussives, anxiolytics, barbiturics, benzodiazepines, hypnotics, laxatives, neuroleptics,

psychostimulants, psychotropes, sedatives, stimulants, anti-inflammatory agents, the pharmacologically acceptable salts thereof, and their mixtures.

As regards anti-inflammatory active principles, the following can be listed:
ibuprofen, acetaminophen, diclofenac, naproxen, benoxaprofen, flurbiprofen, fenoprofen,
5 flubufen, ketoprofen, indoprofen, piroprofen, carprofen, oxaprozine, pramoprofen,
muroprofen, trioxaprofen, suprofen, amineoprofen, tiaprofenic acid, fluprofen, bucloxic
acid, indomethacine, sulindac, tolmetine, zomepirac, tiopinac, zidometacine, acemetacin,
fentiazac, clidanac, oxpinac, mefenamic acid, meclofenamic acid, flufenamic acid,
niflumic acid, tolfenamic acid, diflurisal, flufenisal, piroxicam, sudoxicam or isoxicam, the
10 pharmacologically acceptable salts thereof, and their mixtures.

The dosage form can be a modified release dosage form or a combination of a modified release form and an immediate release form. The active principle can be comprised into modified release microparticles and possibly into immediate release
15 microparticles.

The modified release multiparticulate form of the oral analgesic active principle composition according to the invention, can be:

- a reservoir type form
- 20 • and/or a matricial type form.

"Reservoir type form", is intended to denote, in the present disclosure, a form in which the volume of material containing the active principle is entirely coated by at least a film which controls the diffusion release speed of the active principle through the continuous film (or membrane) which does not include the active principle. This release
25 occurs as a result of the contact of the system with the liquid of the gastro intestinal tract. The active principle containing material is, for example, the active principle in itself, a mixture of pharmaceutical additives or a mixture of pharmaceutical additives with the active principle. The reservoir form comprises, for example, a plurality of individually coated microcapsules or a monolithic system such as coated tablet(s), a tablet or any other
30 pharmaceutical form containing a plurality of coated microcapsules.

"Matricial type form" is intended to denote, in the present disclosure, a form in which the analgesic active principle is dispersed in a solid continuous (polymeric) phase (the matrix) that controls the diffusion release speed of the active principle. Said matrix can or cannot be erodable. Said matrix e.g. consists of pharmaceutically acceptable
35 additives known by the man skilled in the art. The matricial type form includes, for instance, a plurality of matricial micro-granules (matricial elements) containing the active principle. These matricial elements are non-coated or partially coated. The matricial type form can be, e.g., also a monolithic system (matricial element), such as a tablet(s) non-

entirely coated by at least one continuous film, which does not contain any reservoir form. So, the matricial type form can be, e.g. a tablet containing a plurality of active principle immediate release granules or active principle(s) sustained release granules, said granules being dispersed in a polymeric matrix.

5

In a first embodiment of the dosage form according to the invention, the modified release form of the analgesic active principle is a sustained release form with an *in vitro* release profile, such that 70% of the active principle is released over a period of time of between 1 and 24 hours, preferably 2 and 12 hours and even more preferably between 2

10

and 8 hours.

Advantageously, the composition of the individual coating of the microparticles or the matrix of the microparticles, according to the first embodiment, corresponds to one of the two following families A and B:

Family A

15

- -A1- at least one film-forming polymer (P1) which is insoluble in the fluids of the tract, present in a proportion of 50 to 90%, preferably 50 to 80%, by weight on a dry basis with respect to the total mass of the coating composition and composed of at least one water-insoluble cellulose derivative of cellulose,

20

- -A2- at least one nitrogenous polymer (P2), present in a proportion of 2 to 25%, preferably 5 to 15%, by weight on a dry basis with respect to the total mass of the coating composition and composed of at least one polyacrylamide and/or one poly-N-vinylamide and/or one poly-N-vinylactam,

25

- -A3- at least one plasticizer, present in a proportion of 2 to 20%, preferably of 4 to 15%, by weight on a dry basis with respect to the total mass of the coating composition and composed of at least one of the following compounds: glycerol esters, phthalates, citrates, sebacates, esters of cetyl alcohol, castor oil, and salicylic acid;

30

- -A4- at least one surface-active and/or lubricating agent, present in a proportion of 2 to 20%, preferably of 4 to 15%, by weight on a dry basis with respect to the total mass of the coating composition and chosen from anionic surfactants, and/or from nonionic surfactants, and/or from lubricating agents, it being possible for said agent to comprise just one or a mixture of products mentioned above.

Family A can be exemplified as follows:

35

- -A1- ethylcellulose and/or cellulose acetate,
- -A2- polyacrylamide and/or polyvinylpyrrolidone;
- -A3- castor oil,
- -A4- alkali metal or alkaline earth metal salts of fatty acids, stearic acid and/or oleic acid being preferred; polyoxyethylenated sorbitan esters and/or polyoxyethylenated castor

oil derivatives; stearates, preferably calcium stearate, magnesium stearate, aluminium stearate or zinc stearate.

Family B

- 5 • -B1- at least one film-forming polymer insoluble in the gastrointestinal tract fluids;
 • -B2- at least one water-soluble polymer;
 • -B3- at least one plasticizer;
 • -B4- optionally at least one surfactant/lubricant preferably comprising at least an anionic surfactant and/or at least a non-ionic surfactant,

10

Family B can be exemplified as follows:

- -B1-
 - water-insoluble cellulose derivatives, ethyl cellulose and/or cellulose acetate being particularly preferred;
 - 15 - acrylic derivatives;
 - polyvinyl acetates;
 - and mixtures thereof;
- -B2-
 - 20 - water-soluble cellulose derivatives;
 - polyacrylamides; poly-N-vinylamides;
 - poly-N-vinyl lactams;
 - polyvinyl alcohols;
 - polyoxyethylenes;
 - 25 - polyvinylpyrrolidones (the latter being preferred); and mixtures thereof;
- -B3-
 - glycerol and its esters, preferably from the following subgroup: acetylated glycerides, glycerol monostearate, glyceryl triacetate and glycerol tributyrates;
 - phthalates, preferably from the following subgroup: dibutyl phthalate, diethyl phthalate, dimethyl phthalate and dioctyl phthalate;
 - 30 - citrates, preferably from the following subgroup: acetyltributyl citrate, acetyltriethyl citrate, tributyl citrate and triethyl citrate;
 - sebacates, preferably from the following subgroup: diethyl sebacate and dibutyl sebacate;
 - 35 - adipates;
 - azelates;
 - benzoates;
 - vegetable oils;

- fumarates, preferably diethyl fumarate;
- malates, preferably diethyl malate;
- oxalates, preferably diethyl oxalate;
- succinates, preferably dibutyl succinate;
- 5 – butyrates;
- cetyl alcohol esters;
- salicylic acid;
- triacetin;
- malonates, preferably diethyl malonate; ;
- 10 – castor oil (this being particularly preferred);
- and mixtures thereof;
- –B4–
- alkali metal or alkaline earth metal salts of fatty acids, stearic and/or oleic acid
- 15 being preferred;
- polyethoxylated oils, preferably polyethoxylated hydrogenated castor oil;
- polyoxyethylene/polyoxypropylene copolymers;
- polyethoxylated sorbitan esters;
- polyethoxylated castor oil derivatives;
- 20 – stearates, preferably calcium, magnesium, aluminium or zinc stearate;
- stearyl fumarates, preferably sodium stearyl fumarate;
- glycerol behenate;
- and mixtures thereof.

25 Preferably, the coating comprises a single layer, the weight of which represents between 1 and 50 %, preferably between 5 and 40 %, by weight, of the total weight of said microparticles.

30 For further details, in particular qualitative and quantitative details, regarding at least some of the constituents of this coating composition, reference will be made, for example, to European patent EP-B-0 709 087 or to PCT applications WO-A-2004/010983 and WO-A-2004/010984, the content of which is integrated into the present disclosure by way of reference.

35 According to a second embodiment of the solid oral dosage form according to the invention, the modified release solid oral dosage form of analgesic is a sustained release form with an in vitro dissolution behaviour such that:

- the release of analgesic is controlled by means of two distinct triggering mechanisms, one being based on a variation in pH and the other allowing the release of the active principle(s) after a predetermined period of residence in the stomach;
- at constant pH 1.4, the dissolution profile comprises a lag phase of less than or equal to 7 hours, preferably less than or equal to 5 hours, and even more preferably of between 0.25 and 5 hours;
- and the change from pH 1.4 to pH 7.0 results in a release phase that begins without any lag time.

10 More preferably, the modified release solid oral dosage form according to this second embodiment has an *in vitro* dissolution behaviour, measured in an *in vitro* dissolution test, such that:

- less than 20 % of the analgesic is released after 2h at pH 1.4;
- at least 50% by weight of the analgesic is released after 16 h at pH 1.4.

15

According to the second embodiment of the invention, the analgesic active principle is released *in vitro* according to a double trigger mechanism, from microparticles containing said active principle. The coating or the matrix for modified release of the active principle comprises:

- 20
- at least one hydrophilic polymer (I) carrying groups that are ionized at neutral pH,
 - at least one hydrophobic compound (II);

the mean diameter of said microparticles is less than 2000 μm , and preferably between 50 and 800 μm , and even more preferably between 100 and 600 μm .

25 According to another advantageous characteristic, the composite material I-II for the coating for modified release of the active principle with low solubility is such that:

- the II/I weight ratio is between 0.2 and 1.5, preferably between 0.5 and 1.0,
 - and the hydrophobic compound II is selected from products that are crystalline in the solid state and that have a melting point $\text{MpB} \geq 40^\circ\text{C}$, preferably $\text{MpB} \geq 50^\circ\text{C}$, and even
- 30 more preferably $40^\circ\text{C} \leq \text{MpB} \leq 90^\circ\text{C}$.

According to a species of predilection, the hydrophilic polymer (I) is chosen from:

- I.a copolymers of (meth)acrylic acid and of (meth)acrylic acid alkyl ester, and mixtures thereof;
- 35 • I.b cellulose derivatives, preferably cellulose acetates, cellulose phthalates, cellulose succinates and mixtures thereof, and even more preferably hydroxypropylmethylcellulose phthalates, hydroxypropylmethylcellulose acetates, hydroxypropylmethylcellulose succinates and mixtures thereof;

- and mixtures thereof.

The polymers (I) that are even more preferred are copolymers of (meth)acrylic acid and of (meth)acrylic acid alkyl (e.g. C₁-C₆ alkyl) esters. These copolymers are, for example, of the type of those sold by the company Röhm Pharma Polymers under the registered trade marks EUDRAGIT[®], series L and S (such as, for example, EUDRAGIT[®] L100, S100, L30 D-55 and L100-55). These copolymers are anionic enteric copolymers that are soluble in aqueous medium at pHs above those encountered in the stomach.

Still according to the embodiment of predilection, the compound (II) is chosen from the group of products below:

- II.a plant waxes taken on their own or as mixtures with one another;
- II.b hydrogenated plant oils taken on their own or as mixtures with one another;
- II.c mono- and/or di- and/or triesters of glycerol and of at least one fatty acid;
- II.d mixtures of monoesters, of diesters and of triesters of glycerol and of at least one fatty acid;
- and mixtures thereof.

Even more preferably, the compound (II) is chosen from the group of following products:

- hydrogenated cottonseed oil, hydrogenated soybean seed oil, hydrogenated palm oil, glyceryl behenate, hydrogenated castor oil, tristearin, tripalmitin, trimyristin, yellow wax, hard fat or fat that is useful as suppository bases, anhydrous dairy fats, lanolin, glyceryl palmitostearate, glyceryl stearate, lauryl macrogolglycerides, cetyl alcohol, polyglyceryl diisostearate, diethylene glycol monostearate, ethylene glycol monostearate, omega-3 and any mixture thereof,

preferably from the subgroup of following products: hydrogenated cottonseed oil, hydrogenated soybean seed oil, hydrogenated palm oil, glyceryl behenate, hydrogenated castor oil, tristearin, tripalmitin, trimyristin and any mixture thereof.

In practice, and without this being limiting, it is preferable for the compound (II) to be chosen:

- from the group of products sold under the following trade marks: Dynasan[®], Cutina[®], Hydrobase[®], Dub[®], Castorwax[®], Croduret[®], Compritol[®], Sterotex[®], Lubritab[®], Apifil[®], Akofine[®], Softisan[®], Hydrocote[®], Livopol[®], Super Hartolan[®], MGLA[®], Corona[®], Protalan[®], Akosoft[®], Akosol[®], Cremao[®], Massupol[®], Novata[®], Suppocire[®], Wecobee[®], Witepsol[®], Lanolin[®], Incromea[®], Estaram[®], Suppoweiss[®], Gelucire[®], Precirol[®], Emulcire[®], Plurol diisostéarique[®], Geleol[®], Hydrine[®] and Monthyle[®], and mixtures thereof;

- and also from the group of additives for which the codes are as follows: E 901, E 907, E 903 and mixtures thereof;
- and, preferably, from the group of products sold under the following trade marks: Dynasan[®] P60, Dynasan[®] 114, Dynasan[®] 116, Dynasan[®] 118, Cutina[®] HR, Hydrobase[®] 66-68, Dub[®] HPH, Compritol[®] 888, Sterotex[®] NF, Sterotex[®] K, Lubritab[®] and mixtures thereof.

According to another advantageous characteristic of this embodiment, the coating for modified release of the active principle is free of talc.

10 For further details regarding the preparation of these microparticles according to this embodiment, in particular in their embodiment with a neutral core coated with at least one active layer comprising active principle(s) and with at least one outer coating for modified release of the active principle(s), reference will be made to the content of PCT application WO-A-FR03/030878, the content of which is integrated into the present disclosure by way of reference.

20 According to a third embodiment of the invention, the dosage form comprises at least two different populations of microparticles. Each population of modified release micro-particles can correspond either to the first embodiment, or the second embodiment as disclosed above.

According to a fourth embodiment of the invention, the dosage form comprises an immediate release microparticles population and at least one modified release microparticles population.

25

The above-mentioned coated microparticles may have different structures. According to a first structure, some of the microparticles comprise a core containing the active principle and a coating over the core, said coating allowing the modified release of the active principle.

30 According to a second structure, some of the microparticles comprise a core containing a neutral core and at least a layer containing the active principle and coating the neutral core, said microparticle further containing a coating over the core, said coating allowing the modified release of the active principle.

35 Preferably, in the dosage form according to the invention, the antismisuse system is located:

- in microparticles containing said antismisuse agent, and/or
- in a matrix containing said analgesic active principle, and/or

- in a coating of microparticles containing said analgesic active principle, and/or
- in a partial or total over-coating of said dosage form, and/or
- free from said dosage form.

5 As regards the microparticles containing the quenching agent, they can be coated with a film coating, the composition of which is chosen amongst families A and B as disclosed above (first embodiment of the dosage form containing the analgesic active principle).

10 These microparticles containing the quenching agent release the quenching agent with an *in vitro* release profile such that, for example, 70 % of the quenching agent is released for a period of time between 1 and 24h, preferably 2 and 12h, more preferably 2 and 8h.

15 The microparticles containing the quenching agent release the quenching agent can also be coated with a coating as disclosed for the second embodiment mentioned above. The quenching agent is released, for example, with an *in vitro* release profile with an *in vitro* dissolution behavior such that:

- the release of the quenching agent is controlled by means of two distinct triggering mechanisms, one being based on a variation in pH and the other allowing the release of the active principle(s) after a predetermined period of residence in the stomach;
- 20 • at constant pH 1.4, the dissolution profile comprises a lag phase of less than or equal to 7 hours, preferably less than or equal to 5 hours, and even more preferably of between 0.25 and 5 hours;;
- and the change from pH 1.4 to pH 7.0 results in a release phase that begins without any lag time.

25 More preferably, the modified release solid oral dosage form according to this second embodiment has an *in vitro* dissolution behavior, measured in an *in vitro* dissolution test, such that for example:

- less than 20 % of the quenching agent is released after 2h at pH 1.4;
- 30 • at least 50% by weight of the quenching agent is released after 16 h at pH 1.4.

Advantageously, these dosage forms, novel in their structure, their presentation and their composition, are presented in the form of a tablet, a sachet of powder, a sachet of a powder for multidose suspension to be reconstituted, a tablet or a gelatin capsule.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 illustrates example 2. It is a picture of the solutions obtained as follows:

- A : Solution A is oxycodone HCl at 5g/L in water
- 5 • B: Solution B is SDS at 5g/L in water
- A+B: Solution A and B mixed, a precipitate entrapping the oxycodone is formed

EXAMPLES

10

Exemple 1: Oxycodone misuse resistive capsule**Step 1 :**

600 g of Oxycodone HCl and 60 g of Klucel EF® (Hydroxypropyl cellulose / Aqualon) are dissolved in 5000g of water. The solution is sprayed onto 300g of neutral
15 microspheres (Asahi-Kasei) in a GPCG1 Glatt spray coater. 35 g of ethyl cellulose (Ethocel 20 Premium /Dow), 5 g of Plasdane K29/32® (Povidone/ISP), 2.5 g of Cremophor RH 40 (Macrogolglyceroli hydroxystearas / BASF) and 7.5 g of castor oil are dispersed in a 60% isopropanol and 40% acetone mixture. This solution is sprayed onto 350 g of Oxycodone granules previously prepared.

20

Step 2 :

550g of sodium dodecylsulfate (SDS) and 50 g of Klucel EF® (Hydroxypropyl cellulose / Aqualon) are dispersed in 3000g of ethanol. The solution is sprayed onto 250 g of neutral microspheres (Asahi-Kasei) in a GPCG1 Glatt spray coater. 30 g of HPMC
25 (Hypromellose K15MP / Dow), 10 g of Plasdane K29/32® (Povidone/ISP), 2.5 g of Cremophor RH 40 (Macrogolglyceroli hydroxystearas / BASF) and 7.5 g of castor oil are dispersed in a 60% isopropanol and 40% acetone mixture. This solution is sprayed onto 450 g of SDS granules previously prepared.

30 **Step 3 :**

146mg of micro-particules obtained in step 1 are mixed with 105mg of micro-particules obtained in step 2 and put in a size 1 gelatin hard capsule.

If the capsule is broken and emptied in a glass of water a precipitate containing the Oxycodone is obtained.

35

Exemple 2: Quenching of oxycodone hydrochloride by sodium dodecylsulfate in water

In example 2, two solutions were prepared. Solution A is Oxycodone hydrochloride at 5g/L in tap water. Solution B is SDS (sodium dodecylsulfate) at 5g/L in tap water.

- 5 Solution A is added to solution B. The resulting solution A+B is turbid. After a few minutes, a complex containing the oxycodone precipitates. This complex remains stable even if diluted in a larger amount of tap water (more than 2 times).

Therefore, oxycodone cannot be misused, either by oral administration or by injection of a concentrated solution.

CLAIMS

We claim:

- 5 1. An oral solid dosage form containing at least one salt of at least one analgesic active principle, and an anti-misuse system comprising at least one quenching agent, said quenching agent being suitable for inducing complexation of said analgesic active principle salt when the analgesic active principle salt is improperly extracted, notably by a drug abuser, in vitro in solution from said oral solid dosage form.
- 10 2. The dosage form according to claim 1, wherein the desired pharmacological effect of the analgesic active principle is not impaired by the quenching agent when the dosage form is not misused.
- 15 3. The dosage form according to claim 1 or 2, wherein the concentration of analgesic active principle remaining in solution is low after extraction.
4. The dosage form according to any one of the preceding claims, wherein said quenching agent comprises a salt, said salt containing ions which form a complex with said
20 analgesic active principle salt extracted in solution.
5. The dosage form according to any one of the preceding claims, wherein said quenching agent comprises a salt, said salt containing ions, preferably organic ions, having a polarity opposite to that of the analgesic active principle salt in solution, said ions
25 forming a complex with said analgesic active principle salt extracted in solution.
6. The dosage form according to the preceding claim, wherein said ion having a polarity opposite to that of the analgesic active principle salt in solution, is an organic anion.
30
7. The dosage form according to any one of the preceding claims, wherein the quenching agent comprises a salt selected from the group comprising:
 - organic anionic salts, such as sodium dodecyl sulfate or sodium docusate;
 - anionic polymers, such as (meth)acrylic copolymers (for instance Eudragit® S et L),
35 crosslinked acrylic polyacids (for instance, Carbopol), cellulose carboxymethylcellulose and its derivatives, crosslinked carboxymethylcellulose and its derivatives and other polysaccharides (for instance, alginate, xanthane or arabic gum), alginate (sulfonate)propylene glycol;

- mono- or polyvalent salts, such as glucuronates, citrates, acetates, gluconates, succinates, phosphates, glycerophosphates, lactates, trisilicates, fumarates, adipates, benzoates, salicylates, tartrates, sulfonamides, acesulfames;
 - saponified fatty acids, such as the salts of acetic acid, succinic acid, citric acid, stearic acid, palmitic acid, and self emulsifying glyceryl mono-oleates;
 - polyamino acid, proteins or peptides, such as albumins, caseins, globulins and enzymes;
 - and mixtures thereof.
- 10 8. The dosage form according to any one of the preceding claims wherein the quenching agent is a salt of an anionic exchange resin, the cation of which being H^+ , a metallic cation and/or NH_4^+ .
9. The dosage form according to any one of claim 1 to 5, wherein said ion having a polarity opposite to that of the analgesic active principle salt in solution, is a metallic cation, an organic cation, or a mixture thereof.
- 15 10. The dosage form according to the preceding claim wherein the quenching agent comprises a salt selected from the group comprising:
- 20 • metallic cationic salts for example of Ca, Fe, Mg, Zn, in the form of acesulfames, acetates, adipates, benzoates, carbonates, chlorides, citrates, fluorides, fumarates, gluconates, glucuronates, glycerophosphates, hydroxides, iodates, iodides, lactates, oxides, phosphates, trisilicates, phosphates, salicylates, succinates, sulfonamides, tartrates salt;
 - 25 • organic cationic salts, such as quaternary ammonium salts, in particular trimethyl tetradecyl ammonium bromide or benzethonium chloride;
 - cationic polymers, such as chitosan and (meth)acrylic copolymers (for instance, Eudragit ® RS, RL ou E);
 - polyamino acid, proteins or peptides;
 - 30 • and mixtures thereof.
11. The dosage form according to any one of the preceding claims, wherein it comprises modified release units of said analgesic active principle and of said quenching agent.
- 35 12. The dosage form according to the preceding claim, wherein said modified release units comprise microparticles selected from the group comprising: sustained release

microparticles, delayed release microparticles, pulsed release microparticles, and mixtures thereof.

13. The dosage form according to any one of the preceding claims, wherein said dosage
5 form is a multimicroparticulate dosage form.

14. The dosage form according to any one of claims 1 to 13, wherein said dosage form
is a monolithic dosage form.

10 15. The dosage form according to any one of the preceding claims, comprising
microparticles of analgesic active principle and microparticles of quenching agent, said
microparticles having the same size distribution, the same density and being not seevable.

16. The dosage form according to claim 1, comprising a further antimisuse agent.
15

17. The dosage form according to the preceding claim, wherein said further antimisuse
agent comprises an anti-crushing agent.

18. The dosage form according to claims 16 or 17, wherein said further antimisuse
20 agent comprises a viscosity agent.

19. The dosage form according to any one of the preceding claims, wherein the
antimisuse agent is located:

- in microparticles containing said antimisuse agent, and/or
- 25 • in a matrix containing said analgesic active principle, and/or
- in a coating of microparticles containing said analgesic active principle, and/or
- in a partial or total overcoating of said dosage form, and/or
- free from said dosage form.

30 20. The dosage form according to claim 17, wherein said anti-crushing agent
comprises:

- a protective overcoating on said microparticles, said overcoating having at least one of
the following features:
 - viscoelastic properties, to absorb the energy dissipated during crushing;
 - 35 – a low cohesivity, to favour breaking of the overcoating rather than breaking of the
microparticles during crushing;
 - a low surface energy, to favour gliding of the microparticles one on the other
during crushing;

- an ability to form a paste under high shear,
- and/or free additives, i.e. additives that are not contained in nor borne over microparticles, said additives being suitable to impair, or even to prevent completely, the crushing of the pharmaceutical dosage form containing said analgesic active principle.

21. The dosage form according to the preceding claim, wherein said overcoating comprises:

- (i) at least one film forming polymer insuring the cohesion of the overcoating;
- and at least one of the following compounds:
 - (ii) a lubricant/lump agent
 - (iii) a viscoelastic compound
 - (iv) a plasticizer.

22. The dosage form according to the preceding claim, wherein said film-forming polymer (i) is selected from the group comprising cellulose derivatives, acrylic polymers and mixtures thereof.

23. The dosage form according to claim 21, wherein said lubricant/lump agent (ii) is selected from the group comprising:

- stearic acid, stearates, preferably calcium stearate, zinc stearate or magnesium stearate,
- magnesium oxide,
- poloxamers,
- sodium benzoate,
- anionic, cationic or non-ionic surfactants,
- starch, preferably corn starch,
- talc,
- colloidal silica,
- waxes, preferably hydrogenated vegetable oils, and more preferably: cotton hydrogenated oils, soybean hydrogenated oils, palm hydrogenated oils, glycerol behenate, castor hydrogenated oils, tristearines, tripalmitines, trimyristines, yellow wax, white wax, hard fat, dairy anhydrous fat, lanolins, glycerol palmitostearate, glycerol stearates, lauric acid macroglycerids, cetyl alcohols, polyglycyle diisostearate, diethylene glycol monostearate, ethylene monostearate, omega-3 fatty acids, and mixtures thereof,
- suppository fatty base, comprising glycerine, triglycerids, theobroma oils, cocoa butter, and mixtures thereof,
- mixtures thereof.

24. The dosage form according to claim 21, wherein said viscoelastic compound (iii) is selected from the group comprising:

- poly-N-vinylamides,
- 5 • gums,
- fatty alcohols,
- poly-N-vinyl-lactams,
- polyvinyl alcohols,
- polyoxiethylenes,
- 10 • polyethylene glycols,
- polydextroses,
- hydrogenated mono-, di- and polysaccharides,
- polyvinylpyrrolidones, these being preferred,
- and mixtures thereof.

15

25. The dosage form according to claim 21, wherein said plasticizer (iv) is selected from the group comprising:

- glycerol, glycerol esters, preferably acetylated glycerides, glycerylmonostearates, glyceryltriacetate, glyceryltributyrate,
- 20 • phthalates, preferably: dibutylphthalate, diethylphthalate, dimethylphthalate, dioctylphthalate,
- citrates, preferably: acetyltributylcitrate, acetyltriethylcitrate, tributylcitrate, triethylcitrate,
- sebacates, preferably: diethylsebacate, dibutylsebacate,
- 25 • adipates,
- azelates,
- benzoates,
- vegetable oils, preferably: cotton oils, soybean oils, palm oils, castor oils, and mixtures thereof,
- 30 • fumarates, preferably: diethylfumarate,
- malates, preferably: diethylmalate,
- oxalates, preferably: diethyloxalate,
- succinates; preferably: dibutylsuccinate,
- butyrates,
- 35 • cetyl alcohol esters,
- triacetine,
- malonates, preferably: diethylmalonate,
- and mixtures thereof.

26. The dosage form according to claim 20, wherein said additive is selected from the group comprising:
- compression agents, and/or
 - 5 • inert microbeads, and/or
 - gums, and/or
 - viscoelastic compound as defined in claim 24.
27. The dosage form according to claim 18 further comprising viscosity agents which
10 are suitable to increase the viscosity of a liquid extract prepared from said dosage form, so as to impair misuse of said dosage form.
28. The dosage form according to the preceding claim, wherein said viscosity agent is selected from the group comprising:
- 15 • acrylic polyacids and derivatives thereof, and/or
 - polyoxyethylenes, and/or
 - polyvinyl alcohol, and/or
 - polyvinylpyrrolidones, and/or
 - gelatins
 - 20 • cellulose derivatives, for instance hydroxypropylmethylcellulose, methylcellulose, hydroxyethylcellulose, carboxymethylcellulose, hydroxypropylcellulose, and/or
 - polysaccharides, preferably from the group comprising sodium alginate, pectins, guar, xanthanes, carraghenanes, gellanes, and/or
 - mixtures thereof.
- 25 29. The dosage form according to claim 1, wherein said dosage form comprises a plurality of microparticles for the modified release of said analgesic active principle, each microparticles individually comprising a core and a coating on said core, wherein the core comprises at least one analgesic active principle and wherein the coating controls the
30 modified release of said active principle, said microparticles having a mean diameter lower than or equal to 1,000µm
30. The dosage form according to any one of the preceding claims, wherein said analgesic active principle comprises an opioid active principle in the form of a salt.
- 35 31. The dosage form according to the preceding claim, wherein said opioid active principle is selected from the group comprising: anileridine, acetorphine, acetylalphamethylfentanyl, acetyldihydrocodeine, acetylmethadol, alfentanil, allylprodine,

alphacetylmethadol, alphameprodine, alphaprodine, alphamethadol, alphamethylfentanyl,
 alpha-methylthio-fentanyl, alphaprodine, anileridine, atropine, butorphanol, benzethidine,
 benzylmorphine, beta-hydroxyfentanyl, beta-hydroxy-methyl-3-fentanyl,
 betacetylmethadol, betameprodine, betamethadol, betaprodine, bezitramide,
 5 buprenorphine, butyrate de dioxaphetyl, clonitazene, cyclazocine, cannabis, cetobemidone,
 clonitazene, codeine, coca, cocaïne, codoxime, dezocine, dimenoxadol,
 dioxaphetylbutyrate, dipipanone, desomorphine, dextromoramide, dextropropoxyphene,
 diampromide, diethyl-thiambutene, difenoxine, dihydrocodeine, dihydroetorphine,
 dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, diphenoxylate,
 10 dipipanone, drotebanol, eptazocine, ethoheptazine, ethylmethylthiambutene,
 ethylmorphine, etonitazene, ecgonine, ephedrine, ethylmethylthiambutene, ethylmorphine,
 etonitazene, etorphine, etoxeridine, fentanyl, furethidine, heroïne, hydrocodone,
 hydromorphinol, hydromorphone, hydroxypethidine, isomethadone, ketobemidone,
 levallorphan, lofentanil, levomethorphan, levomoramide, levophenacymorphane,
 15 levorphanol, meptazinol, meperidine, metazocine, methadone, methyl-desorphine,
 methyl-dihydro-morphine, methylphenidate, methyl-3-thiofentanyl, methyl-3-fentanyl,
 metopon, moramide, morpheridine, morphine, mppp, myrophine, nalbuphine, narceine,
 nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, nicocodine,
 nicodicodine, nicomorphine, noracymethadol, norcodeine, norlevorphanol, normethadone,
 20 normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, phenadoxone,
 phenoperidine, promedol, properidine, propiram, propoxyphene para-fluorofentanyl,
 pepap, pentazocine, pethidine, phenampromide, phenazocine, phenomorphane,
 phenoperidine, pholcodine, piminodine, piritramide, proheptazine, propanolol, properidine,
 propiram, racemethorphan, racemoramide, racemorphan, remifentanil, sufentanil,
 25 thebaine, thebaine, thiofentanyl, tilidine, trimeperidine, tramadol, pharmacologically
 acceptable salts thereof and their mixtures.

32. The dosage form according to any one of the preceding claims, comprising at least
 one non-analgesic active principle selected from the group comprising: anti-depressants,
 30 amphetamines, anorectics, pain killers, antiepileptics, anitmigraines, antiparkinson agents,
 antitussives, anxiolytics, barbiturics, benzodiazepines, hypnotics, laxatives, neuroleptics,
 psychostimulants, psychotropes, sedatives, stimulants, anti-inflammatory agents, the
 pharmacologically acceptable salts thereof, and their mixtures.

35 33. The dosage form according to claim 1, which is in the form of tablets, powders,
 sachets, or capsules.

1 / 1




FIGURE 1

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2005/012721

A. CLASSIFICATION OF SUBJECT MATTER INV. A61K9/51 A61K9/62		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2004/126428 A1 (HUGHES LYN ET AL) 1 July 2004 (2004-07-01) paragraphs [0011], [0039], [0058]; example 7	1-33
X	WO 2004/004693 A (COLLEGIUM PHARMACEUTICAL) 15 January 2004 (2004-01-15) page 12, line 16 - page 13, line 23 page 18, line 22 - line 26 examples	1-33
X	US 2003/068392 A1 (SACKLER RICHARD) 10 April 2003 (2003-04-10) paragraphs [0024], [0053] - [0056], [0107] - [0110]; examples	1-33
-/-		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family		
Date of the actual completion of the international search 21 March 2006		Date of mailing of the international search report 30/03/2006
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016		Authorized officer Giménez Miralles, J

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2005/012721

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2004/037259 A (GRUENTHAL GMBH; BARTHOLOMAEUS, JOHANNES; KUGELMANN, HEINRICH; LANGNE) 6 May 2004 (2004-05-06) page 11, paragraph 2 - page 13, paragraph 3; examples page 18, paragraph 2 - page 19, paragraph 3	1-33
X	WO 03/013538 A (EURO-CELTIQUE, S.A; WRIGHT, CURTIS, IV; CARPANZO, ANTHONY, E) 20 February 2003 (2003-02-20) examples	1-33
X	WO 2005/016314 A (GRUENTHAL GMBH; BARTHOLOMAEUS, JOHANNES; KUGELMANN, HEINRICH) 24 February 2005 (2005-02-24) example 6	1-33

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2005/012721

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 2004126428	A1	01-07-2004	NONE	
WO 2004004693	A	15-01-2004	AU 2003247876 A1	23-01-2004
			CA 2491572 A1	15-01-2004
			EP 1594467 A1	16-11-2005
			JP 2006500426 T	05-01-2006
US 2003068392	A1	10-04-2003	NONE	
WO 2004037259	A	06-05-2004	AU 2003278133 A1	13-05-2004
			CA 2502965 A1	06-05-2004
			DE 10250084 A1	06-05-2004
			EP 1558257 A1	03-08-2005
WO 03013538	A	20-02-2003	HU 0401066 A2	30-08-2004
WO 2005016314	A	24-02-2005	DE 10336400 A1	24-03-2005
			US 2005031546 A1	10-02-2005